Register to receive a free U.S. Markets for Cardiac Surgery and Heart Valve Devices or a Europe Market Report Suite for Cardiac Surgery Devices report synopsis and brochure
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, recently announced that it has launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new device offers an open-ended design combined with a tip-first closure mechanism to enable easier navigation and placement when operating in minimally-invasive surgery (MIS) environments. The AtriClip PRO•V represents a significant addition to the company’s already deep offerings for epicardial left atrial appendage management. The device received 510(k) clearance in March of 2016, after which time the company introduced the device to a limited number of customers in the U.S. As of today, the product is available to all U.S. customers.
“The AtriClip® franchise continues to be the fastest growing part of our business, and we are excited to add another piece to our portfolio with the AtriClip PRO•V,” said Michael Carrel, President, and CEO of AtriCure. “The advancements with the open-ended design provides a more flexible approach in MIS therapies. Additionally, early experience and feedback from customers utilizing the device to treat patients has been excellent, and we are happy to now make the product available to all customers in the U.S. This platform will also serve as the foundation for future innovation and increasingly less invasive applications of our AtriClip platform.”
The AtriClip PRO•V has identical forces and pressure specifications to the closed-end design of the other AtriClip devices, such as the AtriClip FLEX and the AtriClip PRO2™. The AtriClip PRO•V is also compatible with 12mm ports, making it an ideal choice for minimally invasive approaches. In addition, the unique design allows for the AtriClip PRO•V to be repositioned multiple times before deployment to ensure ideal placement at the base of the appendage.
For Further Information
This report covers the following market segments: tissue heart valves, mechanical heart valves, annuloplasty repair, transcatheter mitral valve repair, transcatheter heart valve implantation, on-pump coronary artery bypass, off-pump coronary artery bypass, endoscopic vessel harvesting, anastomosis assist, cardiac ablation, transmyocardial revascularization, ventricular assist, intra-aortic balloon pumps, artifical hearts, patent foramen ovale, and atrial and ventricular septal devices. Recent reports on the markets for cardiac surgery and heart valve devices cover the U.S. and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.